Elevance Health’s (ELV) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Elevance Health (NYSE:ELV – Free Report) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $478.00 target price on the stock. Other equities research analysts have also recently issued reports about the company. Baird R W cut Elevance Health […]

Leave a Reply

Your email address will not be published.

Previous post MFA Financial, Inc. (NYSE:MFA) Shares Acquired by Bank of Montreal Can
Next post Elevance Health (NYSE:ELV) Earns “Overweight” Rating from Cantor Fitzgerald